Inversago Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Inversago Pharma's estimated annual revenue is currently $2.6M per year.
- Inversago Pharma's estimated revenue per employee is $100,500
Employee Data
- Inversago Pharma has 26 Employees.
- Inversago Pharma grew their employee count by -10% last year.
Inversago Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.4M | 12 | -8% | N/A | N/A |
#2 | $10.7M | 100 | 5% | $39.7M | N/A |
#3 | $47.8M | 238 | N/A | N/A | N/A |
#4 | $15.5M | 77 | 5% | N/A | N/A |
#5 | $345.9M | 1721 | 8% | N/A | N/A |
#6 | $167M | 831 | 8% | N/A | N/A |
#7 | $318.8M | 1586 | 7% | N/A | N/A |
#8 | $27.5M | 137 | -26% | N/A | N/A |
#9 | $0.4M | 4 | 0% | N/A | N/A |
#10 | $66.9M | 333 | N/A | N/A | N/A |
What Is Inversago Pharma?
Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG) and Type 1 Diabetes (T1D), Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
keywords:N/A
N/A
Total Funding
26
Number of Employees
$2.6M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Montreal
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 26 | N/A | N/A |
#2 | $2.4M | 26 | 30% | N/A |
#3 | $4.6M | 26 | 18% | N/A |
#4 | N/A | 26 | 4% | N/A |
#5 | $2.6M | 26 | 8% | N/A |